481 related articles for article (PubMed ID: 34203237)
61. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.
Liu YF; Zhang ZC; Wang SY; Fu SQ; Cheng XF; Chen R; Sun T
Int Immunopharmacol; 2022 Sep; 110():108900. PubMed ID: 35753122
[TBL] [Abstract][Full Text] [Related]
62. Immunotherapy for the treatment of colorectal cancer.
Lumish MA; Cercek A
J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
[TBL] [Abstract][Full Text] [Related]
63. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
64. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.
Cejuela M; Vethencourt A; Pernas S
Curr Oncol Rep; 2022 Dec; 24(12):1801-1819. PubMed ID: 36255603
[TBL] [Abstract][Full Text] [Related]
65. The Application of Omics Technologies in the Research of Neurotoxicology.
Shao W; Li H
Methods Mol Biol; 2021; 2326():143-154. PubMed ID: 34097266
[TBL] [Abstract][Full Text] [Related]
66. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
67. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
68. Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors.
Sobral PS; Luz VCC; Almeida JMGCF; Videira PA; Pereira F
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982981
[TBL] [Abstract][Full Text] [Related]
69. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
Guang MHZ; McCann A; Bianchi G; Zhang L; Dowling P; Bazou D; O'Gorman P; Anderson KC
Leuk Lymphoma; 2018 Mar; 59(3):542-561. PubMed ID: 28610537
[TBL] [Abstract][Full Text] [Related]
70. 10. Role of high dimensional technology in preeclampsia (omics in preeclampsia).
Youssef L; Testa L; Crovetto F; Crispi F
Best Pract Res Clin Obstet Gynaecol; 2024 Feb; 92():102427. PubMed ID: 37995432
[TBL] [Abstract][Full Text] [Related]
71. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
[TBL] [Abstract][Full Text] [Related]
72. Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?
Przybylski DJ; Bergsbaken JJ; Piccolo JK
J Oncol Pharm Pract; 2021 Jun; 27(4):930-938. PubMed ID: 33406979
[TBL] [Abstract][Full Text] [Related]
73. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
74. 404-error "Disease not found": Unleashing the translational potential of -omics approaches beyond traditional disease classification in heart failure research.
Esquivel Gaytan A; Bomer N; Grote Beverborg N; van der Meer P
Eur J Heart Fail; 2024 Jun; 26(6):1313-1323. PubMed ID: 38741225
[TBL] [Abstract][Full Text] [Related]
75. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
[TBL] [Abstract][Full Text] [Related]
76. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
77. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
[TBL] [Abstract][Full Text] [Related]
78. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
Hersi F; Elgendy SM; Al Shamma SA; Altell RT; Sadiek O; Omar HA
Life Sci; 2022 Jul; 300():120573. PubMed ID: 35469916
[TBL] [Abstract][Full Text] [Related]
79. A multi-omics view of the complex mechanism of vascular calcification.
Qian Y; Li L; Sun Z; Liu J; Yuan W; Wang Z
Biomed Pharmacother; 2021 Mar; 135():111192. PubMed ID: 33401220
[TBL] [Abstract][Full Text] [Related]
80. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]